## CME: CME Group Inc. - XLF: Financial Services

### Executive Summary

No thesis match: MRS_20 -0.3% below STRENGTH zone (4.0-10.0%); PEG 5.76 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($261.70)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. CME Group Inc. Stock (NASDAQ: CME) This Week: Shares Rebound on Strong Volume Data, SEC Clearing-House Greenlight — Week Ahead Outlook (Updated Dec. 12, 2025)**
- Source: ts2.tech | 20251213T010903 | Bullish | Relevance: 100%
- CME Group Inc. (NASDAQ: CME) shares rebounded this week, closing at $273.55, driven by a surge in November trading activity which saw a 10% year-over-year increase in average daily volume and record crypto participation. The SEC also approved CME's new securities clearing house, CME Securities Clearing Inc., vital for forthcoming U.S. Treasury and repo clearing mandates. With significant U.S. economic data releases expected next week, CME's core franchises in rates and equity indexes could see increased volatility and trading volumes.

**2. Guarantor: JPMorgan Chase & Co.**
- Source: StreetInsider | 20251215T204618 | Neutral | Relevance: 65%
- JPMorgan Chase Financial Company LLC has issued $1,040,000 Uncapped Dual Directional Barrier Notes linked to the S&P 500 Futures Excess Return Index, due December 14, 2028, with the payments fully and unconditionally guaranteed by JPMorgan Chase & Co. These notes are designed for investors seeking an uncapped return for index appreciation and a capped unleveraged return for index depreciation, provided it remains above a barrier amount. Investors should be aware of the credit risks of both JPMorgan Financial and JPMorgan Chase & Co., and the notes do not pay interest.

**3. Intercontinental Exchange (ICE): Revisiting Valuation After New Expero Data Deal and Strong November Trading Metrics**
- Source: Simply Wall Street | 20251214T142423 | Somewhat-Bullish | Relevance: 62%
- Intercontinental Exchange (ICE) is gaining attention due to a new data deal with Expero and strong November trading metrics. Despite a modest one-year return, ICE's shares appear undervalued according to analysis, with a fair value estimated at $190.29 versus its current price of $163.21. The narrative suggests continued growth through expanding data partnerships and electronic trading platforms, though risks like energy market downturns or integration issues with mortgage tech deals could impact future performance.

**4. J.P. Morgan AM (JPM) offers Ethereum tokenized Treasury fund via Morgan Money**
- Source: Stock Titan | 20251215T140825 | Somewhat-Bullish | Relevance: 61%
- J.P. Morgan Asset Management has launched My OnChain Net Yield Fund (MONY), its first tokenized money market fund, on the public Ethereum blockchain. This 506(c) private placement allows qualified investors to invest in U.S. Treasury securities and repurchase agreements, with daily dividend reinvestment and subscription/redemption options in cash or stablecoins via the Morgan Money platform. The initiative underscores J.P. Morgan's commitment to blockchain-based financial innovation and positions it as a leading GSIB in the tokenized money market space.

**5. Barclays Sticks to Its Buy Rating for KKR & Co (KKR)**
- Source: The Globe and Mail | 20251213T091450 | Neutral | Relevance: 60%
- Barclays analyst Benjamin Budish has reiterated a Buy rating on KKR & Co (KKR) with a price target of $169.00. This follows KKR & Co's strong quarterly revenue of $5.46 billion and net profit of $900.36 million, outperforming the previous year. While Wells Fargo also issued a Buy rating, another firm, TR | OpenAI – 4o, maintained a Hold rating on the company.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Barclays | $304 | $280 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Barclays | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 5 ($1.99M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (+0.4%)
- Blackrock Inc.: 8.7% (+4.1%)
- JPMORGAN CHASE & CO: 5.3% (+55.3%)
- State Street Corpora: 4.5% (-2.0%)
- Geode Capital Manage: 2.6% (+2.2%)

### Key Risks

1. Valuation stretched: PEG 5.8x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 5.76 signals overvaluation risk, limited margin of safety. Forward P/E 23.3x stretched relative to 4% growth. Quality metrics strong (margin 59%). Analyst sentiment positive (1 raises, avg +9%). Insider selling cluster ($2.0M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $98.1B |
| Beta | 0.29 |
| 52W Range | $224.62 - $290.79 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 5.76 |
| Forward P/E | 23.3 |
| Current P/E | 24.4 |
| YoY Growth | 4.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -4.5% to -0.3% (+4.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.3pp (needs >4.0% for momentum thesis). MRS_5 turning positive (2.3%) - potential reversal signal. Underperforming sector by 4.2pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.01x) but short-term weakness (below SMA20). MACD histogram bearish (-0.74), momentum weakening. RSI neutral at 48. OFD pattern: -DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.30% (CS: 32) | Neutral |
| RSI_14 | 48.2 | Neutral |
| MACD Histogram | -0.74 | Bearish |
| vs SMA20 | 0.991x | Below |
| vs SMA50 | 1.002x | Above |
| vs SMA200 | 1.006x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $272.18
- **Stop Loss:** $261.70 (3.9% risk)
- **Target:** $282.66 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 114
- **Position Value:** $31,028.52
- **Portfolio %:** 31.03%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | MOMENTUM (Zone F) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-11 (Est: $2.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.63 | $2.68 | +2.0% |
| 2025Q2 | $2.94 | $2.96 | +0.6% |
| 2025Q1 | $2.81 | $2.80 | -0.3% |
| 2024Q4 | $2.45 | $2.52 | +3.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*